Literature DB >> 32833326

Cystic fibrosis year in review 2019: Section 1 CFTR modulators.

Adrienne P Savant1,2, Susanna A McColley3,4,5.   

Abstract

During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance. To adequately address the large body of CF research published during 2019, the CF year in review will be divided into three sections. This report is the first section, focusing specifically on new research related to cystic fibrosis transmembrane conductance regulator modulator therapy. Additional sections will concentrate on pulmonary and infections research and the multisystem effects of CF. It is an exciting time to be providing care for patients and their families with CF with all the exciting new discoveries that will be shared in these reviews.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  clinical trials; cystic fibrosis; evidence-based medicine and outcomes

Year:  2020        PMID: 32833326     DOI: 10.1002/ppul.25039

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  3 in total

1.  Novel CFTR Modulators for Treating Cystic Fibrosis.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-05-18       Impact factor: 4.632

2.  Bibliometric analysis of chloride channel research (2004-2019).

Authors:  Jingjing Shi; Shuqing Shi; Guozhen Yuan; QiuLei Jia; Shuai Shi; Xueping Zhu; Yan Zhou; Ting Chen; Yuanhui Hu
Journal:  Channels (Austin)       Date:  2020-12       Impact factor: 2.581

Review 3.  Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?

Authors:  Birgitta Strandvik
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.